Answers are grounded in this paper and cite their sources.
The side effects associated with opioids are well described and include nausea and vomiting, bloating, constipation, drowsiness, cognitive impairment, hallucinations, pruritus, myoclonus, urinary retention, postural hypotension and rarely respiratory depression and opioid-induced hyperalgesia.Many of these adverse effects are transient and may be addressed by the temporary reduction of opioid Abstract Context: Constipation is a common side effect of opioid therapy that impairs quality of life, reduces adherence to therapy, and interferes with effective pain control.A prolonged-release (PR) fixed combination of oxycodone and the opioid antagonist naloxone (OXN PR) has been shown to effectively control pain while reducing the incidence of opioid-induced constipation.Objectives: The purpose of this retrospective observational, real-world study was to evaluate the analgesic efficacy of OXN PR and incidence of constipation in outpatients with moderate-severe cancer-related pain who were switched from other opioids as part of their routine care.Methods: Data were collected from a chart review of 270 patients with a confirmed diagnosis of cancer and cancer pain who had received a fixed dose of opioid for at least 4-6 weeks before being switched to OXN PR for at least 4-6 weeks.The primary endpoint was changed in subjective pain intensity score (visual analogue scale) from baseline to 4-6 weeks after the switch, and data were also collected relating to constipation and laxative use. Results:In comparison with pain scores at the switching date, subjective pain was reduced by 53% (mean difference -30.8 mm on visual analogue scale, 95 % confidence interval -33.2 mm to -28.3 mm; P<0.001) after switch to OXN PR.Switching to OXN PR was not associated with an increase in constipation episodes or laxative use.Conclusion: In everyday clinical practice, switching patients with poorly controlled moderate to severe cancer pain to OXN PR can significantly improve pain control without increasing opioid-related constipation.
No takes yet. Share an insight, caveat, or question.
A 2021 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: